Related Experiment Video
Updated: Aug 13, 2026
06:33
Direct Detection of Isolevuglandins in Tissues Using a D11 scFv-Alkaline Phosphatase Fusion Protein and Immunofluorescence
Published on: July 5, 2021
Detection of human MCP-4/CCL13 isoforms by SELDI immunoaffinity capture
Leonardo Rossi1, Ramy Moharram, Brian M Martin
1Department of Human Morphology and Applied Biology, University of Pisa, 56126 Pisa, Italy. leoros@biomed.unipi.it
Journal of Translational Medicine
|January 26, 2006
Summary
Researchers identified two mature isoforms of Monocyte Chemoattractant Proteins 4 (MCP-4/CCL13) in human serum. These isoforms are present both before and after high-dose IL-2 immunotherapy, establishing the primary structure of this important chemokine.
Area of Science:
- Immunology and Biochemistry
- Chemokine Biology and Signaling
Background:
- Monocyte Chemoattractant Proteins 4 (MCP-4/CCL13) is a CC chemokine crucial for eosinophil recruitment to inflammatory sites.
- Elevated serum levels of MCP-4/CCL13 have been observed following high-dose IL-2 immunotherapy.
- The mature, biologically active form of human MCP-4/CCL13 has not been previously purified or structurally characterized.
Purpose of the Study:
- To purify and characterize the mature isoforms of human MCP-4/CCL13 present in serum.
- To establish the primary structure of the biologically relevant forms of MCP-4/CCL13.
- To investigate the presence of MCP-4/CCL13 isoforms before and after IL-2 immunotherapy.
Main Methods:
- Utilized SELDI (Surface-Enhanced Laser Desorption/Ionization) immunoaffinity capture technology.
- Applied advanced proteomic techniques for protein purification and characterization from human serum samples.
Main Results:
- Successfully identified and described two distinct mature isoforms of MCP-4/CCL13.
- Confirmed the presence of these MCP-4/CCL13 isoforms in human serum.
- Demonstrated that both isoforms are detectable both prior to and following high-dose IL-2 immunotherapy.
Conclusions:
- The primary structures of two mature MCP-4/CCL13 isoforms have been established.
- These findings provide critical insights into the composition of MCP-4/CCL13 in serum under different immunological conditions.
- This characterization is essential for understanding MCP-4/CCL13's role in inflammation and immunotherapy responses.
